Trade-Ideas: PerkinElmer (PKI) Is Today's

Trade-Ideas LLC identified PerkinElmer ( PKI) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate. In addition to specific proprietary factors, Trade-Ideas identified PerkinElmer as such a stock due to the following factors:

  • PKI has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $26.2 million.
  • PKI has traded 84,727 shares today.
  • PKI traded in a range 286.6% of the normal price range with a price range of $2.65.
  • PKI traded above its daily resistance level (quality: 532 days, meaning that the stock is crossing a resistance level set by the last 532 calendar days. The resistance price is defined by the Price - $0.01 at the time of the signal).

Stocks matching the 'Barbarian at the Gate' criteria are worthwhile stocks to watch for a variety of factors including historical back testing and volatility. Trade-Ideas targets these opportunities because the stock is exhibiting an unusual behavior while displaying positive price action. In this case, the stock crossed an important inflection point; namely, 'resistance' while at the same time the range of the stock's movement in price is more than twice its normal size. This large range foreshadows a possible continuation as the stock moves higher.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in PKI with the Ticky from Trade-Ideas. See the FREE profile for PKI NOW at Trade-Ideas

More details on PKI:

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, research, environmental, industrial, and laboratory services markets worldwide. The company operates through two segments, Human Health and Environmental Health. The stock currently has a dividend yield of 0.5%. PKI has a PE ratio of 27. Currently there are 6 analysts that rate PerkinElmer a buy, 1 analyst rates it a sell, and 7 rate it a hold.

If you liked this article you might like

PerkinElmer Among Targets Fitting Thermo Fisher's M&A Criteria

PerkinElmer Takes Cautious Approach to M&A

PerkinElmer Medical Imaging Unit Sale Could Be in the Works

Jim Cramer's 'Mad Money' Recap: Short-Term Pain? Try Investing for Long-Term Gain